Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00301106 · ClinicalTrials.gov registry record · Phase 1
Biological Therapy in Treating Women With Breast Cancer That Has Spread to the Liver
A Phase 1 study, sponsored by Max Sung.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00301106: Clinical Trial Phase 1 study, sponsored by Max Sung.
NCT00301106 is a Phase 1 study that was terminated before completion, run by Max Sung. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00301106, a Phase 1 study, was terminated before completion, sponsored by Max Sung.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapy using a gene-modified virus that can make interleukin-12 may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of a gene-modified virus that can make interleukin-12 in treating women with breast cancer that has spread to the liver.
Interventions
- BIOLOGICAL adenovirus-mediated human interleukin-12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2005-10 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00301106
The ClinicalTrials.gov registry entry for NCT00301106 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Max Sung, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which adenovirus-mediated human interleukin-12 is the first listed.
NCT00301106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00301106 about?
NCT00301106 is a clinical study titled "Biological Therapy in Treating Women With Breast Cancer That Has Spread to the Liver". RATIONALE: Biological therapy using a gene-modified virus that can make interleukin-12 may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of a gene-modified virus that can make interleukin-12 in treating w...
What is the current status of trial NCT00301106?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2005-10. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00301106?
The interventions under investigation include: adenovirus-mediated human interleukin-12 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00301106?
This trial is sponsored by Max Sung, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.